Alper Yurci

Alper Yurci

Auto-generated profile, based on publicly available information

Alper Yurci

Department of Gastroenterology, Erciyes University Faculty of Medicine, Kayseri, Türkiye

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
AYAlper Yurci
Alper Yurci
MYMehmet Yucesoy
Mehmet Yucesoy
KUKursad Unluhizarci
Kursad Unluhizarci
ETEdip Torun
Edip Torun
SGSebnem Gursoy
Sebnem Gursoy
OOOmer Ozbakir
Omer Ozbakir

1 September 2007 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AYAlper Yurci
Alper Yurci
KGKadri Guven
Kadri Guven
ETEdip Torun
Edip Torun
SGSebnem Gursoy
Sebnem Gursoy
MBMevlut Baskol
Mevlut Baskol
MYMehmet Yucesoy
Mehmet Yucesoy
Interferon therapy is the cornerstone of chronic hepatitis C treatment. Side effects of interferon include possible triggering or exacerbation of immune diseases in consequence of immunomodulatory effects. We describe the unique case, in which pyoderma gangrenosum and exacerbation of psoriasis were developed 8 weeks after pegylated interferon alpha 2a and ribavirin therapy in a 45-year-old woman. The therapy had to be stopped on account of pyoderma gangrenosum and exacerbation of psoriasis in spite of a biochemical response to the therapy for hepatitis C. The evolution was favorable after stopping treatment. Therefore, we propose this would suggest a possible autoimmune mechanism for the development of pyoderma gangrenosum and exacerbation of psoriasis with pegylated interferon therapy. A susceptible patient, who has an autoimmune disease before interferon therapy, had to be informed that interferons may induce de novo or exacerbate existing immune diseases by immunomodulatory actions. To the best of our knowledge, this is the first case report of pyoderma gangrenosum and psoriasis that resulted from pegylated interferon alpha 2a and ribavirin treatment of chronic hepatitis C.

1 November 2011 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AYAlper Yurci
Alper Yurci
AKAli Osman Kalkan
Ali Osman Kalkan
OOOmer Ozbakir
Omer Ozbakir
AKAhmet Karaman
Ahmet Karaman
ETEdip Torun
Edip Torun
FBFahri Bayram
Fahri Bayram
Metabolic bone disease is common in patients with chronic liver disease. Comparative studies on the efficacies of antiosteoporotic agents in hepatic osteodystrophy have not been conducted yet. The aim of this study was to evaluate the safety and efficacy of different therapeutic regimens on hepatic osteodystrophy. Eighty-one patients (mean age 48.9 ± 10 years; 50 cases with chronic viral hepatitis and 31 patients with cirrhosis) were enrolled in the study. Treatment groups consisted of 61 patients who had reduced T scores in at least one region, selected randomly and treated for 1 year with vitamin D 400 IU, calcitonin 200 IU, alendronate 10 mg, alendronate 70 mg, or risedronate 5 mg. An untreated group consisting of 20 patients who had no reduction in T scores was followed up during the study period. No significant adverse effects, including esophageal variceal hemorrhage, were detected. According to the T score at the end of the first year compared with baseline, significant improvements in bone mineral density were observed at all regions with alendronate 70 mg; improvements at the lumbar spine (LS) and distal radius regions with alendronate 10 mg; at the LS and distal radius regions with risedronate; at the LS region with calcitonin; and at the femoral neck region with vitamin D. All therapeutic regimens seemed to be safe, and oral biphosphonates were the most effective in preventing both cortical and trabecular bone loss in patients with chronic viral liver disease. Larger studies with longer follow-up are warranted in hepatic osteodystrophy of chronic viral liver diseases.

15 October 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
EÜEnver Üçbilek
Enver Üçbilek
AYAbdullah Emre Yıldırım
Abdullah Emre Yıldırım
ZEZeynep Ellik
Zeynep Ellik
ITİlKer Turan
İlKer Turan
BHBüşra Haktanıyan
Büşra Haktanıyan
RIRamazan Idilman
Ramazan Idilman
Background/Aims: The aim of our study was to investigate the underlying causes behind the etiology of cirrhosis in Türkiye. Materials and Methods: The study was comprised of patients with cirrhosis located in the gastroenterology clinics of 28 centers in Türkiye between January 2000 and June 2021. Results: The study group consisted of 4953 cirrhotic patients (median age: 62.2 years, male / female: 58% / 42%). Among the patients, 39% of the patients were compensated, and 61% were decompensated. Furthermore, 47.5% had Child-Pugh class A, 38% had ChildPugh class B, and 14.5% had Child-Pugh class C. The most frequent complaints were abdominal bloating (28%). Ascites (54.2%) was the most common manifestation of decompensation. The median Child-Pugh and MELD-Na scores were 7.0 and 10.0, respectively. The most common cause of cirrhosis was chronic viral hepatitis (43%), followed by cryptogenic cirrhosis (CC) (19%), metabolic dysfunction-associated steatotic liver disease (MASLD)-related cirrhosis (13%), and alcohol-related cirrhosis (11%). Among the 950 patients with CC, 416 had metabolic abnormalities. If these 416 CC patients with metabolic abnormalities were categorized as having MASLDrelated cirrhosis, the proportion of MASLD-related cirrhosis increased to 21%. Thirteen percent of the patients were diagnosed with HCC, while 4% had extrahepatic malignancy. Female breast cancer (18%) and colorectal cancer (18%) were the most frequent extrahepatic malignancies. Conclusion: Viral hepatitis remains the main cause of cirrhosis in Türkiye. However, its prevalence seems to be declining, whereas the prevalence of steatotic liver disease-related cirrhosis is increasing. Cite this article as: Üçbilek E, Yıldırım AE, Ellik Z, et al. Changing trends in the etiology of cirrhosis in Türkiye: A multicenter nationwide study. Turk J Gastroenterol. 2024;35(10):772-777.

27 June 2012 in Modern Rheumatology
Verified
Journal Article
Closed access
munis dündarmunis dündar
munis dündar
AKAslihan Kiraz
Aslihan Kiraz
BBBurhan Balta
Burhan Balta
EEElif Funda Emirogullari
Elif Funda Emirogullari
GZGokmen Zararsiz
Gokmen Zararsiz
MBMevlut Baskol
Mevlut Baskol
Objectives: Familial Mediterranean fever (FMF) is one of the most serious inherited inflammatory disorders among Jewish, Armenian, Turkish and Arab populations. The imbalance between pro- and anti-inflammatory cytokines may play a role in its etiology. We have investigated whether tumor necrosis factor-alpha (TNF-α) and plasminogen activator inhibitor 1 (PAI-1) gene polymorphisms are associated with FMF and evaluated the relationship between these polymorphisms and genotypic manifestation of FMF. Methods: We investigated single nucleotide polymorphisms of the TNF-α promoter at positions −308 G/A and the PAI-1 4G/5G gene polymorphism in peripheral blood leukocytes collected from 177 individuals with FMF with different genotype combinations. All of the polymorphisms of TNF-α and PAI-1 were detected by PCR and restriction fragment length polymorphism analysis. Results: There were no association between the TNF-α/308 genotypes and mutations in FMF. In contrast, the PAI-1 4G/5G gene polymorphism may have a significant effect in FMF disease. Conclusions: Screening with PAI-1 gene polymorphism tests may be beneficial for tracing future FMF patients. However, further investigations are needed to reach a conclusion on the association between PAI-1 polymorphisms and FMF.

1 September 2007
Verified
Journal Article
Closed access
SGSebnem Gursoy
Sebnem Gursoy
KGKadri Guven
Kadri Guven
TATamer Arikan
Tamer Arikan
AYAlper Yurci
Alper Yurci
ETEdip Torun
Edip Torun
MYMehmet Yucesoy
Mehmet Yucesoy